VH298

01/01/2022 - "In the present study, EVs were reported as a new treatment for diabetic wounds by delivering VH298 into endothelial cells. "
01/01/2022 - "Here, we loaded EVs with VH298 (VH-EVs) to exert an on-target enhancement of proangiogenic capacity in diabetic wound. "
01/01/2022 - "VH298 holds great promise to improve angiogenesis by stabilizing HIF-1α which is reported at low level in diabetic wounds. "
01/01/2022 - "Collectively, our findings suggest a promising EV-based strategy for the VH298 delivery to endothelial cells and provide a new bioactive dressing for diabetic wound treatment. "
01/01/2019 - "VH298 or PBS was locally injected into wounds in rat models with streptozotocin- (STZ-) induced hyperglycaemia, the wound tissues were harvested, and haematoxylin-eosin (HE) and Masson trichrome staining and immunohistochemical processes were conducted. "

01/01/2021 - "we established HTFs hypoxia model in vitro, meanwhile the HIF-1α agonist VH298 or inhibitor KC7F2 was added to HTFs, and the normoxia group was used as a control. "
11/04/2016 - "VH298 represents a high-quality chemical probe of the HIF signalling cascade and an attractive starting point to the development of potential new therapeutics targeting hypoxia signalling."
01/01/2021 - "VH298 and KC7F2 upregulated and downregulated the levels of VEGF and TGF-β, respectively, suggesting that HIF-1α upregulates and downregulates the levels of VEGF and TGF-β in HTFs under hypoxia, respectively. "
01/01/2019 - "Von Hippel-Lindau (VHL) Protein Antagonist VH298 Improves Wound Healing in Streptozotocin-Induced Hyperglycaemic Rats by Activating Hypoxia-Inducible Factor- (HIF-) 1 Signalling."

01/01/2021 - "We previously reported the design and characterization of VHL inhibitors VH032 and VH298 that block the VHL:HIF-α interaction, activate the HIF transcription factor, and induce a hypoxic response, which can be beneficial to treat anemia and mitochondrial diseases. "

01/01/2019 - "VH298 enhanced rFb functions, promoted hUVEC angiogenesis, and accelerated wound healing in the rat model mimicking diabetes mellitus."

01/01/2021 - "We previously reported the design and characterization of VHL inhibitors VH032 and VH298 that block the VHL:HIF-α interaction, activate the HIF transcription factor, and induce a hypoxic response, which can be beneficial to treat anemia and mitochondrial diseases. "